Vanda Pharmaceuticals Inc
VNDA
Get informed when a big investor buys or sells
+ FollowMarket Cap$242.46M
Close$
$-2.67
166.7% downside
Current Fair Value
166.7% downsideOvervalued by 166.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $242.46 Million |
|---|---|
| Enterprise Value | $186.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.74 |
| Beta | 0.69 |
| Outstanding Shares | 60,226,570 |
Return
| Return on Equity | -124.83% |
|---|---|
| Return on Assets | -66.64% |
| Return on Invested Capital | -74.14% |
Valuation & Multiples
| P/E Ratio | -0.87 |
|---|---|
| PEG | -0.67 |
| Price to Sales | 1.34 |
| Price to Book Ratio | 1.34 |
| Enterprise Value to Revenue | 0.86 |
| Enterprise Value to EBIT | -1.01 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$61.92 M
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$-0.72
Average shareholder expectationRevenue Estimate
$69.20 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 35.72% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.32%▼ 83.25% |
|---|---|
| Total Invested | $917,198▼ 99.70% |
| Investors Holding | 19▼ 158.00% |
ESG Score
No data
About Vanda Pharmaceuticals Inc
CEO: Mihael Polymeropoulos Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.